Skip Navigation

Advertise|Press|Contact|FAQ|CWConnect

Bookmark/Print/Share

Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Oncology
 Disease Category: Hodgkin's Disease
Location: United States, CA

Trial Information

A Phase II Study of Brentuximab Vedotin as Salvage Therapy for Hodgkin Lymphoma Prior to Autologous Hematopoietic Stem Cell Transplantation

You have been asked to participate in this research study because you have Hodgkin Lymphoma that is no longer responding or never responded to your first treatment. The purpose of this research study is to evaluate the safety and effectiveness of brentuximab vedotin before autologous hematopoietic stem cell transplant (return to the research participant of previously collected immature blood cells). A second purpose is to see if treatment with brentuximab vedotin has any effect on the collection of stem cells from the research participant’s blood. Tumor samples from standard of care biopsies or surgeries will be obtained for laboratory tests to study the effect of the drug on tumor cells. Your treatment on this study is expected to last for four cycles (21 days) of therapy or approximately 12 weeks. After your treatment on this study is over, your medical condition will continue to be followed for three weeks.

Patient Inclusion/Exclusion Criteria:


- See http://clinicaltrials.coh.org for additional information.


City of Hope
1500 East Duarte Road
Duarte, CA 91010-3000
Phone: 866-896-HOPE (4673)

View Map

Research Center Information: City of Hope

DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the clinical trials industry. The information provided in this service is designed to help patients find clinical trials that may be of interest to them, and to help patients contact the centers conducting the research. CenterWatch is neither promoting this research nor involved in conducting any of these trials.